Prospects for the use of ATR inhibitors to treat cancer

Jill M. Wagner, Scott H. Kaufmann

Research output: Contribution to journalReview article

40 Scopus citations

Abstract

ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.

Original languageEnglish (US)
Pages (from-to)1311-1334
Number of pages24
JournalPharmaceuticals
Volume3
Issue number5
DOIs
StatePublished - Jul 30 2010

    Fingerprint

Keywords

  • ATM
  • ATR
  • Chemotherapy
  • Chk1
  • Replication checkpoint

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this